SCHEMBL4255235

SCHEMBL4255235

Cc1ccc(C(N)=O)c(Br)c1.O=S(=O)(O)/C=C/c1cccs1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.40
CYP2D6 P10635 1/20 0.40
NPC1 O15118 6/20 0.38
RAB9A P51151 6/20 0.38
SMN1; SMN2 Q16637 4/20 0.38
ALOX5 P09917 1/20 0.38
PTGS1 P23219 1/20 0.38
PTGS2 P35354 1/20 0.38
TP53 P04637 1/20 0.38
HTT P42858 2/20 0.38
LMNA P02545 3/20 0.37
ALDH1A1 P00352 2/20 0.37
GAA P10253 1/20 0.37
HPGD P15428 1/20 0.37
MAPT P10636 6/20 0.37
POLB P06746 1/20 0.36
HCAR2 Q8TDS4 1/20 0.36
MEN1 O00255 3/20 0.35
KMT2A Q03164 3/20 0.35
KDM4E B2RXH2 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4260077 0.88 PTGS1 (0.42) CYP1A2CYP2D6NPC1RAB9ASMN1; SMN2
SCHEMBL4260434 0.86 MAPT (0.38) CYP1A2CYP2D6NPC1RAB9ASMN1; SMN2
SCHEMBL4256748 0.84 MAPT (0.44) CYP1A2CYP2D6NPC1RAB9ASMN1; SMN2
SCHEMBL27738925 0.81 SMN1; SMN2 (0.46) NPC1RAB9ASMN1; SMN2PTGS2TP53
SCHEMBL5416951 0.81 SMN1; SMN2 (0.46) NPC1RAB9ASMN1; SMN2PTGS2TP53
SCHEMBL4256510 0.81 MAPT (0.42) CYP1A2CYP2D6NPC1RAB9ASMN1; SMN2
SCHEMBL4255236 0.80 NLRP3 (0.46) CYP1A2CYP2D6NPC1RAB9ASMN1; SMN2
SCHEMBL4255233 0.80 NLRP3 (0.46) CYP1A2CYP2D6NPC1RAB9ASMN1; SMN2
SCHEMBL4253732 0.80 NPC1 (0.42) CYP1A2CYP2D6NPC1RAB9ASMN1; SMN2
SCHEMBL4256676 0.80 ALOX5 (0.39) NPC1RAB9ASMN1; SMN2ALOX5PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1904471-B1 HETEROARYLETHENYL DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS HOFFMANN LA ROCHE (CH) 2009-10-21 EP claimed
US-7208506-B2 Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents HOFFMANN-LA ROCHE INC. (US) 2007-04-24 US claimed
US-20070010564-A1 Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents HOFFMANN-LA ROCHE INC. 2007-01-11 US claimed
EP-1904471-B1 HETEROARYLETHENYL DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS HOFFMANN LA ROCHE (CH) 2009-10-21 EP disclosed
US-7208506-B2 Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents HOFFMANN-LA ROCHE INC. (US) 2007-04-24 US disclosed
US-20070010564-A1 Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents HOFFMANN-LA ROCHE INC. 2007-01-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010564-A1 Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents CYP3A43, CYP1A1, CYP3A5 CYP1A2 11/4885CYP2D6 8/4885NPC1 254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.